Cargando…

Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review

BACKGROUND: Pituitary metastasis (PM) from differentiated thyroid cancer (DTC) is extremely rare and may adversely affect outcomes. We aimed to assess the characteristics and outcomes of patients with PM from DTC. METHODS: We systematically reviewed the literature on publications on PM and the diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilerhunmwuwa, Nosakhare Paul, Wasifuddin, Mustafa, Perry, Jamal, Hakobyan, Narek, Inyang, Lawrence, Zavgorodneva, Zhanna, Gasparyan, Lilit, Tahir, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284638/
https://www.ncbi.nlm.nih.gov/pubmed/37350806
http://dx.doi.org/10.14740/wjon1593
_version_ 1785061445549948928
author Ilerhunmwuwa, Nosakhare Paul
Wasifuddin, Mustafa
Perry, Jamal
Hakobyan, Narek
Inyang, Lawrence
Zavgorodneva, Zhanna
Gasparyan, Lilit
Tahir, Muhammad
author_facet Ilerhunmwuwa, Nosakhare Paul
Wasifuddin, Mustafa
Perry, Jamal
Hakobyan, Narek
Inyang, Lawrence
Zavgorodneva, Zhanna
Gasparyan, Lilit
Tahir, Muhammad
author_sort Ilerhunmwuwa, Nosakhare Paul
collection PubMed
description BACKGROUND: Pituitary metastasis (PM) from differentiated thyroid cancer (DTC) is extremely rare and may adversely affect outcomes. We aimed to assess the characteristics and outcomes of patients with PM from DTC. METHODS: We systematically reviewed the literature on publications on PM and the different DTC histologic types (papillary, follicular, and Hurthle cell cancers). Three databases (PubMed, Embase, and Scopus) were searched for articles published from 1967 to 2022. Survival time was estimated as the period from the first treatment of PM to the time of death or last follow-up. RESULTS: Twenty-five articles comprising 27 cases that met the eligibility criteria were identified using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The median age of the patients was 60 years (23 - 86). A preponderance of females (66.7%) with PM most commonly reported papillary thyroid cancer (55.6%). This was followed by follicular thyroid cancer (37.0%) and Hurthle cell cancer (7.4%). The most common presentations were headache, nausea, and vomiting, with visual symptoms in 44.4%. Diabetes insipidus was an infrequent finding (7.4%). The median time from diagnosis or first treatment of DTC to the diagnosis of PM was 3 years (0 - 25). The most common endocrine abnormality was hyperprolactinemia (63.2%), while the most frequently deficient hormone was luteinizing hormone (50%). The most common treatment modality for PM was a combination of radiotherapy and surgery with or without radio-iodine. At the end of the follow-up, 30% of the patients died. Only 33.3% of the patients achieved complete resolution of symptoms. The overall median survival time was 12 months (3 - 108). There was a moderate inverse correlation between the age of patients and survival, which was, however, not statistically significant (rs = -0.45, P = 0.103). CONCLUSION: PM from DTC is extremely rare, and Hurtle cell cancer appears to be the least associated with PM. Diabetes insipidus is a rare initial manifestation of PM from DTC. Complete resolution of symptoms is less likely to be achieved in PM from DTC. Older age may confer an increased survival tendency, probably due to more intracranial space volume in older people compared to the younger population. Larger studies are needed to examine the relationship between age and survival in PM from DTC. Also, more observational data are required to determine the predictors of survival and compare the efficacy of the different treatment modalities in patients with PM from DTC.
format Online
Article
Text
id pubmed-10284638
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-102846382023-06-22 Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review Ilerhunmwuwa, Nosakhare Paul Wasifuddin, Mustafa Perry, Jamal Hakobyan, Narek Inyang, Lawrence Zavgorodneva, Zhanna Gasparyan, Lilit Tahir, Muhammad World J Oncol Review BACKGROUND: Pituitary metastasis (PM) from differentiated thyroid cancer (DTC) is extremely rare and may adversely affect outcomes. We aimed to assess the characteristics and outcomes of patients with PM from DTC. METHODS: We systematically reviewed the literature on publications on PM and the different DTC histologic types (papillary, follicular, and Hurthle cell cancers). Three databases (PubMed, Embase, and Scopus) were searched for articles published from 1967 to 2022. Survival time was estimated as the period from the first treatment of PM to the time of death or last follow-up. RESULTS: Twenty-five articles comprising 27 cases that met the eligibility criteria were identified using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The median age of the patients was 60 years (23 - 86). A preponderance of females (66.7%) with PM most commonly reported papillary thyroid cancer (55.6%). This was followed by follicular thyroid cancer (37.0%) and Hurthle cell cancer (7.4%). The most common presentations were headache, nausea, and vomiting, with visual symptoms in 44.4%. Diabetes insipidus was an infrequent finding (7.4%). The median time from diagnosis or first treatment of DTC to the diagnosis of PM was 3 years (0 - 25). The most common endocrine abnormality was hyperprolactinemia (63.2%), while the most frequently deficient hormone was luteinizing hormone (50%). The most common treatment modality for PM was a combination of radiotherapy and surgery with or without radio-iodine. At the end of the follow-up, 30% of the patients died. Only 33.3% of the patients achieved complete resolution of symptoms. The overall median survival time was 12 months (3 - 108). There was a moderate inverse correlation between the age of patients and survival, which was, however, not statistically significant (rs = -0.45, P = 0.103). CONCLUSION: PM from DTC is extremely rare, and Hurtle cell cancer appears to be the least associated with PM. Diabetes insipidus is a rare initial manifestation of PM from DTC. Complete resolution of symptoms is less likely to be achieved in PM from DTC. Older age may confer an increased survival tendency, probably due to more intracranial space volume in older people compared to the younger population. Larger studies are needed to examine the relationship between age and survival in PM from DTC. Also, more observational data are required to determine the predictors of survival and compare the efficacy of the different treatment modalities in patients with PM from DTC. Elmer Press 2023-06 2023-06-11 /pmc/articles/PMC10284638/ /pubmed/37350806 http://dx.doi.org/10.14740/wjon1593 Text en Copyright 2023, Ilerhunmwuwa et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ilerhunmwuwa, Nosakhare Paul
Wasifuddin, Mustafa
Perry, Jamal
Hakobyan, Narek
Inyang, Lawrence
Zavgorodneva, Zhanna
Gasparyan, Lilit
Tahir, Muhammad
Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
title Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
title_full Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
title_fullStr Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
title_full_unstemmed Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
title_short Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
title_sort pituitary metastases from differentiated thyroid cancers: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284638/
https://www.ncbi.nlm.nih.gov/pubmed/37350806
http://dx.doi.org/10.14740/wjon1593
work_keys_str_mv AT ilerhunmwuwanosakharepaul pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT wasifuddinmustafa pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT perryjamal pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT hakobyannarek pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT inyanglawrence pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT zavgorodnevazhanna pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT gasparyanlilit pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview
AT tahirmuhammad pituitarymetastasesfromdifferentiatedthyroidcancersasystematicreview